Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31499182 | 1.00 | MRGPRX4 (0.50) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL24253043 | 0.83 | CD274 (0.43) | PDCD1CD274 | |
| SCHEMBL24252986 | 0.81 | PDCD1 (0.47) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL31499181 | 0.81 | PDCD1 (0.47) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL3932203 | 0.80 | MAOB (0.54) | MRGPRX4PDCD1CD274MAOBMAOA | |
| SCHEMBL24252540 | 0.80 | MRGPRX4 (0.47) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL14854689 | 0.78 | MRGPRX4 (0.76) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL28472232 | 0.77 | PDCD1 (0.60) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL24253040 | 0.77 | PDCD1 (0.55) | MRGPRX4PDCD1CD274CCR5FFAR1 | |
| SCHEMBL22874523 | 0.77 | MAOB (0.62) | MRGPRX4FFAR1FFAR4MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4198017-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022033303-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | MRGPRX4 3340/4885PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.